Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CURX · NASDAQ · Pharmaceutical Preparations
Curanex Pharmaceuticals (CURX) · oqro.io/stocks/CURX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.41−0.0296 (−0.67%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Curanex Pharmaceuticals is on record in SEC filings since 2006.
No open-market sale by an insider of Curanex Pharmaceuticals (CURX) was filed with the SEC in the last 90 days.
No trade in Curanex Pharmaceuticals (CURX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−47.6% (−$4.00) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $8.41 on Nov 20, 2025 to $4.41 on Nov 20, 2026 (−47.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Jericho, Ny.
Last 12 months
−47.6%
Market value
$6.92M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5,945 shares sold short (0.4% of shares outstanding), +14.4% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $1.58M, at Sep 30, 2026
Net income, last 12 months
−$12.3M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Against the S&P 500 over the year
Since Nov 18, 2025, CURX is down 55.9% and the index fund is up 4.5%: 60 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CURX moves
Beta 0.8 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
No Schedule 13D or 13G filing on CURX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest annual report filed Mar 30, 2026. Read the filing
40 risk factor headings in this report. There is no earlier annual report to compare it with.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 3,000 words.
We are a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and to improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. We are committed to “Bringing hope and healing through the wisdom of plants.
And 6 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 18.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (2.6% on ATS, 15.7% with other brokers), below its 8-week average of 37.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (19.0%), SIGMA X2 (16.1%), CROSSSTREAM (13.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Top officer leaving
“The term of the CEO Agreement begins on the Effective Date and ends on the fourth anniversary of the Effective Date, until terminated earlier by the parties under the terms of the CEO Agreement.”
8-K on sec.govTop officer leaving
“Compensatory Arrangements of Certain Officers On December 31, 2025, Haiyan Yang informed Curanex Pharmaceuticals Inc, a Nevada corporation (the “Company”) of her resignation as Chief Financial Officer and Treasurer of the Company, effective immediately.”
8-K on sec.govSaid its annual or quarterly report would be late
NT 10-Q on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.